T. Rowe Price Associates’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-953,914
| Closed | -$71.8M | – | 3082 |
|
|
2022
Q2 | $71.8M | Sell |
953,914
-3,008,738
| -76% | -$226M | 0.01% | 754 |
|
|
2022
Q1 | $106M | Buy |
3,962,652
+151,084
| +4% | +$4.06M | 0.01% | 710 |
|
|
2021
Q4 | $182M | Buy |
3,811,568
+525,687
| +16% | +$25.1M | 0.02% | 584 |
|
|
2021
Q3 | $218M | Buy |
3,285,881
+391,786
| +14% | +$26M | 0.02% | 523 |
|
|
2021
Q2 | $226M | Buy |
2,894,095
+373,052
| +15% | +$29.1M | 0.02% | 528 |
|
|
2021
Q1 | $238M | Sell |
2,521,043
-24,742
| -1% | -$2.34M | 0.02% | 503 |
|
|
2020
Q4 | $310M | Buy |
2,545,785
+594,067
| +30% | +$72.4M | 0.03% | 416 |
|
|
2020
Q3 | $171M | Buy |
1,951,718
+44,489
| +2% | +$3.89M | 0.02% | 522 |
|
|
2020
Q2 | $123M | Buy |
1,907,229
+564,690
| +42% | +$36.5M | 0.02% | 576 |
|
|
2020
Q1 | $60M | Sell |
1,342,539
-152,887
| -10% | -$6.83M | 0.01% | 723 |
|
|
2019
Q4 | $93.2M | Buy |
1,495,426
+280,569
| +23% | +$17.5M | 0.01% | 690 |
|
|
2019
Q3 | $45.7M | Buy |
1,214,857
+324,807
| +36% | +$12.2M | 0.01% | 903 |
|
|
2019
Q2 | $36.2M | Buy |
+890,050
| New | +$36.2M | 0.01% | 987 |
|